Summit Therapeutics SMMT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's additional paid-in capital?
- Summit Therapeutics (SMMT) reported additional paid-in capital of $3.02B in Q1 2026.
- How has Summit Therapeutics's additional paid-in capital changed year-over-year?
- Summit Therapeutics's additional paid-in capital increased by 87.0% year-over-year, from $1.62B to $3.02B.
- What is the long-term trend for Summit Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Summit Therapeutics's additional paid-in capital has grown at a 58.6% compound annual growth rate (CAGR), from $293.37M to $2.95B.
- What does additional paid-in capital mean?
- The amount of money shareholders paid for shares above their par value.
- How do you interpret additional paid-in capital?
- Increases in this account are typically driven by equity financing rounds or the exercise of stock options, indicating capital infusion.
- How does additional paid-in capital compare across companies?
- Reflects the historical success of capital raises and equity-based compensation programs across the industry.